Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel in Women With Increased Breast Cancer Risk
NCT04570956Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Jul 2021
- Primary completion
- Oct 2024
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tamoxifen, afimoxifene in breast cancer, sponsored by Mayo Clinic. Started Jul 2021; status: terminated.
02
Drugs
tamoxifenafimoxifene
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04570956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04570956.